Submit Manuscript  

Article Details

SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study

[ Vol. 16 , Issue. 4 ]


Georgios Kyriakos, Lourdes V. Quiles-Sanchez, Anna Garmpi, Paraskevi Farmaki*, Konstantina Kyre, Spyridon Savvanis, Vasileios K. Antoniou and Eleni Memi   Pages 258 - 265 ( 8 )


A new group of hypoglycemic drugs has been used to treat diabetes type 2. This group is active sodium glucose co-transporter (SGLT2) or SGLT2 inhibitors. It has been shown that besides the treatment of diabetes, this drug class is responsible for the mildness of the cardiovascular events shown in patients with diabetes type 2. However, there is an intriguing question regarding the range of SGLT2 inhibitors and if there is a difference between them or if there is a class effect among their results. EMPA-REG OUTCOME trial and the CVD-study are used to answer this question. Additional information from the DECLARE-TIMI 58 and Dapa-HF trials is studied.


SGLT2 inhibitors, T2DM, diabetes type 2 mellitus, EMPA-REG OUTCOME trial, CVD-REAL study, class effect, cardiovascular events.


Seccion de Endocrinologia y Nutrition, Hospital General Universitario Santa Lucia, Cartagena, Centro de Salud Jesús Marín, Murcia, Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, 1st Department of Pediatrics, “Aghia Sophia Children’s Hospital” Medical School, National and Kapodistrian University of Athens, Athens, Internal Medicine Department, KAT General Hospital, Athens, Department of Internal Medicine General Hospital of Athens "Elpis", Athens, Breast Surgical Clinic, Saint Savvas Anti-Cancer Hospital, Athens, Unit of Endocrinology, Diabetes Mellitus and Metabolism, Aretaieion University Hospital, Medical School of Athens, Ethnikon and Kapodistrian University of Athens, Athens

Graphical Abstract:

Read Full-Text article